ERα及PR在乳腺癌患者中的表达及与疾病预后关系探讨

Expression of ERα and PR in breast cancer and its relationship with disease prognosis

目的探讨ERα及PR在乳腺癌患者中的表达及与疾病预后的关系。方法选取我院100例原发性乳腺癌患者检测ERα及PR水平,然后根据检测结果评价乳腺癌早期诊断以及病情监测、预后评估的价值。结果ERα与PR的表达随着乳腺癌临床分期的逐渐升高,阴性表达也逐渐升高,在临床分期中比较Ⅰ期与Ⅱ期、Ⅱ期与Ⅲ期之间差异具有统计学意义(P<0.05)。结论 ERα与PR的表达主要随着临床肿瘤的分期而发生显著变化,反映其对于乳腺癌分化程度可以作为重要的检测指标,为监测临床疗效及判断预后等方面提供有利依据。

Objective To investigate the expression of ERα and PR in breast cancer and its relationship with the prognosis of the disease. Methods The levels of ERα and PR were detected in 100 patients with primary breast cancer. And then based on the test results, their values in early diagnosis of breast cancer and disease monitoring, prognostic were evaluated. Results The expression of ERα and PR gradually increased with the clinical stage of breast cancer, while negative expression also gradually increased. There was statistically significant difference between Ⅰ and Ⅱ, and between Ⅱand Ⅲ in the clinical stage （P〈0.05）. Conclusion The expression of ERα and PR mainly changes with the staging of clinical tumor, which reflects the degree of differentiation of breast cancer can be used as an important test index, providing a favorable basis for monitoring clinical efficacy and judging the prognosis.